Galecto Biotech AB (Lund, Sweden) is an early-stage orphan drug development company.
The company is focusing on novel therapeutics for fibrosis and inflammatory-related diseases, including the lung disease Idiopathic Pulmonary Fibrosis (IPF).
The lead program is in clinical development and addresses a novel therapeutic target for IPF called Galectin-3.
For more information, please contact:
Phone: +45 4081 4889